Core Insights - Nxera Pharma is a technology-powered biopharma company focused on developing specialty medicines to address unmet medical needs in Japan and globally [1][3]. Company Overview - Nxera Pharma has established a new-generation commercial business in Japan aimed at developing and commercializing innovative medicines for a large and growing market in the APAC region [2]. - The company employs approximately 400 professionals across key locations including Tokyo, Osaka, London, Cambridge, Basel, and Seoul, and is listed on the Tokyo Stock Exchange under the ticker 4565 [4]. Pipeline and Research - Nxera is advancing a pipeline of over 30 active programs from discovery to late clinical stages, utilizing its unique NxWave™ discovery platform [3]. - The pipeline focuses on addressing major unmet needs in rapidly growing medical fields such as neurology/neuropsychiatry, metabolic diseases, and immunology and inflammation [3]. Recent Developments - Neurocrine Biosciences presented new positive data from the Phase 2 study of NBI-1117568 for schizophrenia at the ASCP 2025 Annual Meeting, which is relevant to Nxera's interests in the neurology sector [1].

Core Viewpoint - Fobi AI Inc. has entered into a share purchase agreement to sell its wholly owned German subsidiary, Fobi AI Germany GmbH, for a total of EUR 1,540,000, which includes a cash purchase price of EUR 1,400,000 and an additional EUR 140,000 to be paid on behalf of Fobi by the purchaser [1][2]. Group 1: Transaction Details - The total payment for the acquisition is EUR 1,540,000, comprising EUR 1,400,000 in cash and EUR 140,000 to be paid by the purchaser to the acquired company [2]. - The acquired company will grant Fobi a non-exclusive, worldwide, irrevocable, and sublicensable license for the "Passcreator Software" for a total price of EUR 140,000, with a term of 48 months post-transaction closing [3]. Group 2: Strategic Implications - The CEO of Fobi stated that the sale of the German subsidiary is a strategic decision aimed at enhancing the company's financial position and supporting future growth without further diluting shareholder value [4]. - The company has been preparing for its next evolution by aligning with transformative shifts in AI and Web3, indicating a focus on advancing its business model [5]. Group 3: Company Background - Fobi, founded in 2017 in Vancouver, Canada, is a leading AI and data intelligence company that helps businesses digitally transform and leverage customer data for personalized experiences [7]. - The company collaborates with major global organizations across various sectors, including retail, insurance, and entertainment, and is recognized as a technology leader in North America and Europe [8].

Group 1 - Jena Acquisition Corporation II priced its initial public offering (IPO) of 20,000,000 units at $10.00 per unit, with trading set to begin on the NYSE under the ticker symbol "JENA.U" on May 29, 2025 [1] - Each unit consists of one Class A ordinary share and one right to receive one-twentieth of a Class A ordinary share upon the completion of a business combination [1] - The offering includes a 45-day option for the underwriter, Santander, to purchase an additional 3,000,000 units to cover over-allotments [2] Group 2 - A registration statement for the securities became effective on May 28, 2025, and the offering is expected to close on May 30, 2025, subject to customary closing conditions [3] - Jena Acquisition Corporation II is a blank check company formed to effect a merger or similar business combination, focusing on leveraging the expertise of its management team [4] - The company intends to identify a target business that can benefit from the historical expertise of its co-founders, William P. Foley, II and Richard N. Massey [4]

Los Angeles, CA and Vancouver, BC, May 28, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig") and Streamex Exchange Corporation ("Streamex"), collectively referred to as the combined company, today announced the appointment of Mitch Williams, CFA, as Chief Investment Officer significantly bolstering the companies’ leadership team and advancing the mission to tokenize real world assets and bring commodity markets on-chain. Key Highlights of the Appointment: Mr. Mitch Williams, form ...

TORONTO, May 28, 2025 (GLOBE NEWSWIRE) -- CF Energy Corp. (TSX-V: CFY) (“CF Energy” or the “Company”, together with its subsidiaries, the “Group”), an energy provider in the People’s Republic of China (the ”PRC” or “China”), announces that the Company has filed its unaudited interim consolidated financial results for the three-month period ended March 31, 2025. The unaudited condensed interim consolidated financial statements and Management’s Discussion and Analysis (“MD&A”) can be downloaded from www.seda ...

VANCOUVER, British Columbia, May 28, 2025 (GLOBE NEWSWIRE) -- AIP Realty Trust (the “Trust” or “AIP Realty”) (TSXV:AIP.U) today announced its financial results for the three months ended March 31, 2025. All dollar amounts are stated in U.S. dollars. Q1 2025 Highlights The demand for light industrial flex facilities is continuing to drive rental rate increases, and the Eagle Court property is demonstrating robust leasing momentum. While the Trust aims to minimize vacancies and has been successful in this end ...

Core Insights - Fate Therapeutics is presenting clinical data from its Phase 1 study of FT819, an off-the-shelf CAR T-cell therapy for moderate-to-severe systemic lupus erythematosus (SLE) at the EULAR 2025 conference [1][2] - The study evaluates the safety and efficacy of FT819 with a fludarabine-free conditioning regimen, aiming to enhance patient access and therapeutic outcomes [2][4] Company Overview - Fate Therapeutics is a clinical-stage biopharmaceutical company focused on developing induced pluripotent stem cell (iPSC)-derived cellular immunotherapies [5][6] - The company has established a leadership position in creating multiplexed-engineered master iPSC lines and manufacturing off-the-shelf iPSC-derived cell products [6] Product Platform - The iPSC product platform allows for unlimited self-renewal and differentiation into all cell types, enabling the creation of well-defined and uniform engineered cell products [4][6] - The platform is supported by over 500 issued patents and 500 pending patent applications, highlighting its innovative approach and potential for broad patient application [4]

Core Points - HI-VIEW RESOURCES INC. announced a non-brokered private placement of up to 4,800,000 units at a price of $0.10 per unit, aiming for gross proceeds of up to $480,000 [1][2] - Each unit consists of one common share and one transferable common share purchase warrant, with the warrant allowing the purchase of an additional share at $0.12 for 36 months [2] - Directors and officers may participate in the private placement, which is classified as a related party transaction and is expected to be exempt from certain formal requirements [3] - The net proceeds will be used for exploration activities and general corporate purposes, with a potential finder’s fee of up to 10% applicable [4] - HI-VIEW is focused on mineral exploration in Canada, holding a 100% interest in the Babine BC Copper-Gold property and other claims in the Toodoggone region, covering over 9,749 hectares [5]

Core Insights - Eton Pharmaceuticals has received FDA approval for KHINDIVI, the first and only hydrocortisone oral solution, aimed at pediatric patients with adrenocortical insufficiency [1][3][9] - The commercial launch of KHINDIVI is expected in the week of June 2, with projected combined peak sales of KHINDIVI and ALKINDI SPRINKLE exceeding $50 million annually [1][6] Product Details - KHINDIVI is formulated as a 1mg/ml oral solution, designed for easy dosing without the need for refrigeration or mixing, making it suitable for patients with swallowing difficulties [2][4] - The product is indicated for replacement therapy in pediatric patients aged five years and older with adrenocortical insufficiency [9] Market Context - There are over 5,000 pediatric patients in the U.S. diagnosed with adrenal insufficiency, highlighting a significant market opportunity for KHINDIVI [6] - Eton's existing commercial team will promote KHINDIVI alongside ALKINDI SPRINKLE, providing additional treatment options for patients and caregivers [5][7] Strategic Partnerships - KHINDIVI will be available exclusively through Anovo, a specialty pharmacy, which will also manage the Eton Cares Program to assist patients with prescription fulfillment and financial support [7][8] Company Overview - Eton Pharmaceuticals focuses on developing treatments for rare diseases and currently has eight commercial products, including KHINDIVI and ALKINDI SPRINKLE [41]

Core Points - Astrotech Corporation has appointed Jennifer Cañas as Chief Financial Officer effective May 22, 2025 [1] - The Board expressed confidence in Ms. Cañas' leadership and experience, highlighting her strong performance since joining the company [2] - Ms. Cañas has over 20 years of experience in senior financial roles, including her previous position as Controller at The Texas Water Company [2] - She is a Certified Public Accountant and graduated Cum Laude with a Bachelor of Science degree in accounting from the University of Houston – Clear Lake [3] - Ms. Cañas is committed to leading the team with integrity and aims to deliver value for shareholders [4] Company Overview - Astrotech Corporation is a mass spectrometry company that develops and commercializes scalable companies through its subsidiaries [4] - Subsidiaries include 1st Detect, AgLAB, Pro-Control, BreathTech, and EN-SCAN, each focusing on different markets such as security, agriculture, and environmental testing [4]